Medical network - on February 24, eight years later, has been praised by the industry focus on the new medical insurance directory finally officially fell to the ground!
Yesterday (23 February), people club department posted on the printing of the national basic medical insurance, inductrial injury insurance and maternity insurance drug catalogue (2017 edition) > notification ", published in 2017 edition of the national basic medical insurance, inductrial injury insurance and maternity insurance drug catalogue.
2009 medicare catalog adjustment has spawned dozens of sales billions of varieties, for the pharmaceutical industry, this course is one of the most anticipated policy this year. The rule of medical insurance directory adjustment is once every five years, for the feast, the pharmaceutical industry has already waited for eight years. The birth of the new directory, which means 1.5 trillion medical market is also expected to refactoring.
▍ Chinese medicine enterprises into the biggest winner
23 afternoon, director-general of the department of the ministry of social health insurance Chen Jinfu in department website online interview was introduced, the new medical insurance directory of western medicine, proprietary Chinese medicine section contains medicine, 2535, from 2009, 339 new version catalogue, rising by about 15%. Chinese medicines, including western medicine, 1297, 1238. Chinese medicine yinpian part did not make an adjustment, still continue to use the provisions of the 2009 drugs directory.
Analysts said that, in the medical insurance directory adjustment of traditional Chinese medicine enterprise benefit the beat expectations, so to speak, there are more than two hundred varieties were swapped in the list, it is not expected, after the industry completely and medicine for more than 100, biological medicine and only a few varieties.
Proprietary Chinese medicine supplementary, almost unanimously recognized as the Chinese traditional medicine enterprises became the biggest winner. Blue parker notice, by the good news to stimulate, today afternoon medicine plate straight pull litre, as of the closing, including hk pharmaceutical, kang edge pharmaceutical, tasly, sunflower pharmaceutical industry listed companies, several related Chinese medicine because of many varieties are shortlisted for the new health insurance directory, with different amplitude increase, even to harden.
▍ children's drugs, the innovation medicine suffers bestow favor on
According to Chen Jinfu introduction, the new medical insurance directory key consideration to existing drugs directory does not cover treatment, mechanism as well as the major disease, mental disease, pediatric gynecological medicines, such as optimizing the directory structure, optimizing varieties of high cost performance and support medical technology innovation, by expanding to promote medical products competition in clinical medicine, etc.
From the point of publish the catalogue of the new health care, children's drugs, innovation, major disease medication, and the new larger proportion of national medicine. The new directory added 91 children's medicine varieties, the list of drugs clearly applies to children's medicines or dosage forms to about 540.
At the same time, adjust the catalogue, in the past, on the basis of overall consideration, more prominent: encourage the development of medicine industry technology innovation through adding negotiation directory, focus on the price expensive, good curative effect, the innovation of the technology innovation has significant value medicine to medical insurance directory.
Have to mention the innovation medicine and heavy disease medicine is also full of harvest. For the new health insurance directory "hydrochloric acid for ek," is a typical example. According to beida pharmaceutical industry to provide the blue parker, "hydrochloric acid for ek," is China's first independent research and development of small molecules targeting anticancer drugs, fill in the blank in this field in our country, open a new era of targeted drugs for treatment of cancer in our country, won the national science and technology progress award, China's industrial awards honor.
It is understood that from 2008 to 2016 in the first half of our country's approval of innovative medicine and biological products, the vast majority were included in the 2017 edition of pharmaceutical medicine catalogue or negotiation. At the same time, the treatment of cancer, mental illness, hemophilia, major diseases such as diabetes, cardiovascular disease, commonly used drugs, also enjoy the same treatment.
▍ health charged fees into keyword
On February 20, the ministry of finance, people club department, who planning commission jointly issued "on strengthening the basic medical insurance fund budget management give play to the role of medical insurance fund control of opinion". "Opinion" is put forward for the medical insurance fund to implement real-time monitoring, grueling.
Macro-reforms, capitation payment is carried out, according to the payment methods, such as a bed, pay medical institutions pay standard, actual cost is lower than contract balance part by retention of medical institutions; Of the actual cost more than pay the standard, exceed a share shall be borne by the medical establishment, for the quality of the reasonable cost overruns can be on the basis of negotiations, Shared by medical institutions and medical insurance fund.
On January 16, the national development and reform commission issued "notice about push press disease charging work, request the local secondary and all public hospitals above to select a certain number of disease to implement press disease to collect fees, city public hospital comprehensive reform pilot area for shall not be less than 100 by the end of 2017. At the same time, the "notice" published 320 planted catalog, for charge around push press disease to choose from.
As the highly anticipated new medical insurance directory, a long-awaited health care payment reform should also not far away. In national policy, under the impetus of the wave after wave of health control cost obviously keyword is already open in 2017 years. Looked from the whole situation of the medical insurance directory adjustment, countries have obvious dilute the attitude of the directory. Under the health control cost big move, for drug firms, the directory is a threshold, access to hospital and health care payment standard is the top priority. In the future, in the health care environment, the interests of all parties of the game will be more obvious.
Right, no matter how medicare fee, for drug companies, health insurance directory of "a" and "into" will bring significant change to revenue. Some analysts believe that new directory or by singling out the latest version of health care medicines, the future market is the fastest can be evident in a year. Kang pharmaceutical toxic heat of ning, for example, the drug sales income is 198 million yuan in 2009, after entering the medical insurance directory, but in 2010 sales revenue reached 1.4 billion yuan, 2015 revenue to turn over seven times. So, for a drug firms, once the drug is included in the medical insurance directory, quick measures as necessary, and this is all the drug companies want to squeeze into the root cause of the medical insurance directory.
The new medicare drug directory changes into the, finally, we take a look at, the higher-ups to directory adjustment, proprietary Chinese medicine the old version of the varieties of medical insurance directory comparison, from easy to recruit mining network arrangement.
|
